Role of biochemical markers in the management of osteoporosis

ABSTRACT Estrogen and bone health form a cornerstone of osteoporosis management. Diagnosis of osteoporosis is performed using bone mineral density (BMD), despite the limitations associated with this. Within the last 25 years, numerous bone turnover markers (BTM) have been developed, and this has led to a marked improvement in drug development for osteoporosis and understanding of fast bone losers. Estrogen research has provided landmark research on understanding the relationship between osteoporosis and BTMs. Clinical studies have illustrated how measurement of BTMs can assist in prediction of rapid bone loss, future fractures and, most importantly, the fracture efficacy of drugs. The BTMs provide information independent of BMD and fracture history. In addition, changes in bone turnover within 1 month predict later changes in BMD, which allows for early efficacy and prognostic measures. The aim is to provide a careful review of the possibilities that implementation of BTMs into clinical practice have provided, while placed in a historical context. The primary focus is on how the BTMs have revolutionized clinical trials on osteoporosis drugs through their ability to supplement bone mass measurements and fracture efficacy endpoints.

[1]  P. Camacho,et al.  Prediction of Fracture Risk in Patients with Osteoporosis: A Brief Review , 2015, Women's health.

[2]  M. Karsdal,et al.  The development and characterization of an ELISA specifically detecting the active form of cathepsin K. , 2013, Clinical biochemistry.

[3]  Ann E. Maloney,et al.  Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. , 2012, Bone.

[4]  M. Karsdal,et al.  Use of Bone Turnover Markers in Clinical Osteoporosis Assessment in Women: Current Issues and Future Options , 2011, Women's health.

[5]  N. Bjarnason,et al.  [Sinus thrombosis in a healthy female taking oral contraceptives]. , 2011, Ugeskrift for laeger.

[6]  H. Dimai,et al.  The effect of PTH(1–84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial , 2011, Osteoporosis International.

[7]  E. Yu,et al.  Acute decline in serum sclerostin in response to PTH infusion in healthy men. , 2011, The Journal of clinical endocrinology and metabolism.

[8]  S. Cummings,et al.  WHO absolute fracture risk models (FRAX): Do clinical risk factors improve fracture prediction in older women without osteoporosis? , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  A. LaCroix,et al.  Oral contraceptive use and bone density change in adolescent and young adult women: a prospective study of age, hormone dose, and discontinuation. , 2011, The Journal of clinical endocrinology and metabolism.

[10]  C. Cooper,et al.  Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[11]  T. Spector,et al.  Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Claus Christiansen,et al.  Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel‐group study in patients with type 2 diabetes on stable insulin therapy , 2011, Diabetes/metabolism research and reviews.

[13]  C. Hurson,et al.  The role of Dkk1 in bone mass regulation: Correlating serum Dkk1 expression with bone mineral density , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[14]  S. Cummings,et al.  Effects of denosumab on bone turnover markers in postmenopausal osteoporosis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  M. Karsdal,et al.  Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis. , 2011, Endocrine reviews.

[16]  C. Cooper,et al.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards , 2011, Osteoporosis International.

[17]  E. Posvar,et al.  Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  H. Stellbrink,et al.  Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  L. Melton,et al.  Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  M. Karsdal,et al.  Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? , 2010, Clinical biochemistry.

[21]  Jacques P. Brown,et al.  Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis , 2010, BMC musculoskeletal disorders.

[22]  M. Karsdal,et al.  Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation , 2010, BMC musculoskeletal disorders.

[23]  M. Karsdal,et al.  Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[24]  R. Rizzoli,et al.  Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  Richard Eastell,et al.  Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  R. Eastell,et al.  The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. , 2010, Bone.

[27]  M. Karsdal,et al.  The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. , 2010, Osteoarthritis and cartilage.

[28]  J. Eisman,et al.  Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[30]  R. Eastell,et al.  Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. , 2009, Bone.

[31]  D. Fernández-García,et al.  Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. , 2009, Maturitas.

[32]  J. Holst,et al.  Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. , 2009, Bone.

[33]  M. Karsdal,et al.  Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[34]  P. Delmas,et al.  Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. , 2009, Clinical therapeutics.

[35]  M. Karsdal,et al.  Influence of food intake on the bioavailability and efficacy of oral calcitonin. , 2009, British Journal of Clinical Pharmacology.

[36]  M. Karsdal,et al.  A Pharmacokinetic and Pharmacodynamic Comparison of Synthetic and Recombinant Oral Salmon Calcitonin , 2009, Journal of clinical pharmacology.

[37]  C. Christiansen,et al.  Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin , 2008, BMC clinical pharmacology.

[38]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  M. Karsdal,et al.  Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin , 2008, BMC clinical pharmacology.

[40]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[41]  J. S. San Martin,et al.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[42]  S. Majumdar,et al.  Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. , 2008, The Journal of clinical endocrinology and metabolism.

[43]  H. Jick,et al.  Use of thiazolidinediones and fracture risk. , 2008, Archives of internal medicine.

[44]  M. Karsdal,et al.  Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies , 2008, Osteoporosis International.

[45]  J. Rissanen,et al.  Secreted Tartrate-Resistant Acid Phosphatase 5b is a Marker of Osteoclast Number in Human Osteoclast Cultures and the Rat Ovariectomy Model , 2008, Calcified Tissue International.

[46]  E. Wooltorton,et al.  Diabetes drug pioglitazone (Actos): risk of fracture , 2007, Canadian Medical Association Journal.

[47]  A. C. Yazici,et al.  Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. , 2007, The Journal of clinical endocrinology and metabolism.

[48]  M. Allende-Vigo.  The use of biochemical markers of bone turnover in osteoporosis. , 2007, Puerto Rico health sciences journal.

[49]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[50]  I. Reid,et al.  The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. , 2007, The Journal of clinical endocrinology and metabolism.

[51]  Claus Christiansen,et al.  Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases , 2007, Osteoporosis International.

[52]  J. Holst,et al.  Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. , 2007, Bone.

[53]  C. Christiansen,et al.  Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study , 2007, Climacteric : the journal of the International Menopause Society.

[54]  M. Karsdal,et al.  An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice , 2006, European Journal of Clinical Pharmacology.

[55]  C. Christiansen,et al.  Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. , 2006, Arthritis and rheumatism.

[56]  B. Månsson,et al.  Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[57]  L. Tankó,et al.  The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients , 2006, Cancer Epidemiology Biomarkers & Prevention.

[58]  M. Karsdal,et al.  In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? , 2005, Assay and drug development technologies.

[59]  P. Delmas,et al.  Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[60]  L. Palermo,et al.  One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. , 2005, The New England journal of medicine.

[61]  G. Dalsky,et al.  Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  M. Karsdal,et al.  Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. , 2005, The American journal of pathology.

[63]  A. Bertolotto,et al.  Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. , 2004, The Journal of clinical endocrinology and metabolism.

[64]  M. Hochberg,et al.  Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  C. Christiansen,et al.  Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  M. C. Ovejero,et al.  The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[67]  C. Christiansen,et al.  Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study , 2004, Osteoporosis International.

[68]  C. Christiansen,et al.  Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. , 2004, Bone.

[69]  M. Inaba,et al.  Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline , 2004, Journal of Bone and Mineral Metabolism.

[70]  Anders Isaksson,et al.  Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  J. Reginster,et al.  Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. , 2003, Maturitas.

[72]  C. Christiansen,et al.  Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. , 2003, Maturitas.

[73]  E. Barrett-Connor,et al.  Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[74]  R. Eastell,et al.  The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women , 2002, BJOG : an international journal of obstetrics and gynaecology.

[75]  C. Christiansen,et al.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.

[76]  D O Slosman,et al.  Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[77]  C. Christiansen,et al.  Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.

[78]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[79]  P. Delmas,et al.  Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  F. Hirahara,et al.  The Predictive Value of Biochemical Markers of Bone Turnover for Bone Mineral Density in Postmenopausal Japanese Women , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  P. Alexandersen,et al.  Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. , 2000, Bone.

[82]  C. Fledelius,et al.  Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. , 2000, The Biochemical journal.

[83]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[84]  S. Cummings,et al.  Biochemical Markers of Bone Turnover and Prediction of Hip Bone Loss in Older Women: The Study of Osteoporotic Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[85]  C. Christiansen,et al.  Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.

[86]  C. Christiansen,et al.  Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. , 1999, Bone.

[87]  C. Christiansen,et al.  Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. , 1998, Clinical chemistry.

[88]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[89]  W. O'Fallon,et al.  Relationship of Bone Turnover to Bone Density and Fractures , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[90]  P. Qvist,et al.  Characterization of Urinary Degradation Products Derived from Type I Collagen , 1997, The Journal of Biological Chemistry.

[91]  B. Riis,et al.  Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. , 1997, Bone.

[92]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[93]  C. Christiansen,et al.  High bone turnover is associated with low bone mass in both pre- and postmenopausal women. , 1996, Bone.

[94]  C. Christiansen.  Osteoporosis: diagnosis and management today and tomorrow. , 1995, Bone.

[95]  C. Christiansen,et al.  Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. , 1995, The Journal of clinical endocrinology and metabolism.

[96]  C. Christiansen,et al.  Immunoassay for quantifying type I collagen degradation products in urine evaluated. , 1994, Clinical chemistry.

[97]  P. Delmas,et al.  Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. , 1994, The Journal of clinical endocrinology and metabolism.

[98]  B. Riis,et al.  Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. , 1991, BMJ.

[99]  C. Christiansen.  Selection of postmenopausal women for estrogen therapy. , 1989, Postgraduate medicine.

[100]  C. Christiansen,et al.  PREDICTION OF RAPID BONE LOSS IN POSTMENOPAUSAL WOMEN , 1987, The Lancet.

[101]  C. Christiansen,et al.  BONE MASS AFTER WITHDRAWAL OF OESTROGEN REPLACEMENT , 1981, The Lancet.

[102]  C. Christiansen,et al.  BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPY , 1981, The Lancet.

[103]  F. Kainberger,et al.  Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[104]  M. Karsdal,et al.  Optimising Antiresorptive Therapies in Postmenopausal Women , 2012, Drugs.

[105]  M. Karsdal,et al.  Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy , 2009, European Journal of Clinical Pharmacology.

[106]  I. Reid,et al.  The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. , 2007, The Journal of clinical endocrinology and metabolism.

[107]  M. Karsdal,et al.  Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? , 2006, Drugs.

[108]  P. Delmas.  Hormone replacement therapy in the prevention and treatment of osteoporosis , 2005, Osteoporosis International.

[109]  A. Hofman,et al.  Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. , 2004, Bone.

[110]  R. Eastell,et al.  Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. , 2004, Bone.

[111]  A. Liesegang.  Possibilities of monitoring bone metabolism in ruminants--an overview of the methods in use. , 2003, Acta veterinaria Scandinavica. Supplementum.

[112]  C. Christiansen,et al.  Mechanism of circadian variation in bone resorption. , 2002, Bone.

[113]  R. Eastell,et al.  Preanalytical Variability of Biochemical Markers of Bone Turnover , 2000, Osteoporosis International.

[114]  R. Eastell,et al.  The Use of Biochemical Markers of Bone Turnover in Osteoporosis , 2000, Osteoporosis International.

[115]  J. Stepan,et al.  Prediction of Bone Loss in Postmenopausal Women , 2000, Osteoporosis International.

[116]  P. Garnero,et al.  Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene , 1999, Osteoporosis International.

[117]  D. Hans,et al.  Do Markers of Bone Resorption Add to Bone Mineral Density and Ultrasonographic Heel Measurement for the Prediction of Hip Fracture in Elderly Women? The EPIDOS Prospective Study , 1998, Osteoporosis International.

[118]  C. Christiansen,et al.  Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. , 1997, Scandinavian journal of clinical and laboratory investigation.

[119]  G. N. Kent.  Standardization of marker assays--pyridinoline/deoxypyridinoline. , 1997, Scandinavian journal of clinical and laboratory investigation. Supplementum.